BiomX Inc. (NYSEAMERICAN:PHGE) Sees Large Growth in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) was the target of a large increase in short interest in July. As of July 31st, there was short interest totaling 481,974 shares, an increase of 153.2% from the July 15th total of 190,323 shares. Currently, 4.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,706,839 shares, the days-to-cover ratio is currently 0.3 days.

BiomX Stock Down 5.1%

NYSEAMERICAN:PHGE traded down $0.01 during trading hours on Friday, reaching $0.15. The company had a trading volume of 1,003,685 shares, compared to its average volume of 1,917,864. The stock has a 50-day moving average of $0.32 and a two-hundred day moving average of $2.35. BiomX has a one year low of $0.12 and a one year high of $12.29. The firm has a market capitalization of $1.73 million, a PE ratio of -0.05 and a beta of 1.35.

Get BiomX alerts:

BiomX (NYSEAMERICAN:PHGE – Get Free Report) last issued its quarterly earnings data on Wednesday, May 20th. The company reported $7.38 earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that BiomX will post -5.85 earnings per share for the current year.

Hedge Funds Weigh In On BiomX

An institutional investor recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new stake in BiomX Inc. (NYSEAMERICAN:PHGE – Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX as of its most recent SEC filing. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Company Profile

(Get Free Report)

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.

Further Reading

• Five stocks we like better than BiomX
• Is Best Buy the AI Winner Hiding in the Electronics Aisle?
• Applied Materials Beat Everything but Wall Street’s Expectations for Margins
• Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
• Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing

Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.